Our Blog
AEMPS publishes recommendations during the crisis period by COVID-19 in Spain
Exceptional measures applicable to clinical trials to manage problems arising from the COVID-19 emergency
Exceptional measures applicable to clinical trials to manage problems arising from the COVID-19 emergency
From Sermes CRO we would like to share with you, The Spanish Agency for Medicines and Health Products (AEMPS), as the national authority competent for the authorization of clinical trials, has proposed a series of recommendations of exceptional application during the duration of the COVID-19 crisis in Spain.
These measures are designed to preserve the activities of the trials as far as possible, ensuring patient care, protecting their safety and well-being and preserving the traceability of the actions implemented in this situation emergency.
These recommendations include activities related to:
- Scheduled face-to-face visits of trial patients
- Recruitment of new patients
- Access to trial treatment
- Motoring visits
- Transferring patients between centres
- Clinical trials in Spain targeting the research of new medicines against COVID-19
To read the original document and detailed information, click on this link: NI_MUH_04-2020_AEMPS Clinical trials_COVID-19_EN
